Ra Pharma’s Cyclomimetic Technology To Help Merck With Difficult Targets
This article was originally published in The Pink Sheet Daily
In its first partnership, Ra, focused on solutions for intracellular protein-protein reactions, could earn up to $200 million by helping Merck to discover and develop drug candidates for protein targets in several undisclosed therapeutic areas.
You may also be interested in...
Just out of stealth mode, privately held biotech closes second tranche of $27 million Series A financing and announces first drug program will pursue an oral kallikrein inhibitor for prevention of hereditary angioedema.
Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.